BlueSphere Bio, Inc.
TCR-engineered T cell therapies for cancer and rare diseases
- Sector
- Biotech
- Headquarters
- PITTSBURGH, PA
- Founded
- 2017
- Latest Form D
- $46M, Dec 2020
- Total capital
- $56M
- Grants
- —
- No SBIR or STTR on record
- Sector median 1 award
- Raised
- $56M
- 2 Form D · Dec 2020
- 70 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 22
- 0 granted · 22 pending
- 11× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $45,637,472 | |
| Private capital raised | Form D · SEC | $10,000,016 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3384 | MouSensor, Inc. | — | — |
| 3385 | AGEX THERAPEUTICS INC | — | $19M |
| 3386 | Ultragenyx Pharmaceutical Inc. | — | $109M |
| 3387 | BlueSphere Bio, Inc. | — | $56M |
| 3388 | Life Biosciences LLC | — | $54M |
| 3389 | PhaseBio Pharmaceuticals Inc | — | $64M |
| 3390 | OPUS GENETICS INC. | — | $47M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David ApelianDirector · Executive Officer
- Jeanne CunicelliDirector
- Tal HeppenstallDirector
- Alan KormanDirector
- Robert LinDirector
- Mark ShlomchikDirector · Executive Officer
- Warren ShlomchikExecutive Officer
Patents
- T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1application
- T Cell Receptors Targeting Minor Histocompatibility Antigen ACC-1application
- T Cell Receptors Targeting An NPM1 Neoantigenapplication
- T Cell Receptors Targeting A NPM1 Neoantigenapplication
- T Cell Receptors Targeting Minor Histocompatibility Antigen LRH-1application
- T Cell Receptors Targeting Minor Histocompatibility Antigen ACC-1application
- Methods For Identifying T Cell Receptors (tcrs) That Bind Antigensapplication
- T Cell Receptors Targeting Minor Histocompatibility Antigen HA-2application
- T Cell Receptors Targeting A NPM1 Neoantigenapplication
- Allogeneic T Cells For Treatment Of Hematological Malignanciesapplication
- Allogeneic T Cells For Treatment Of Hematological Malignancisapplication
- Methods For Identifying T Cell Receptors (TCRs) that Bind Antigensapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.